IP Library Patent Application 18830683
Patent Application
App. No. 18/830,683

COMPOSITION AND METHOD FOR GENERATING IMMUNITY TO BORRELIA BURGDORFERI

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/830,683
Abstract

Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids of SEQ ID NO:1 and one or more adjuvant. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition

Claims (28)

1 . An immunogenic composition, comprising

a peptide, comprising at least any eight consecutive amino acids from amino acid 186 to amino acid 196 of SEQ ID NO: 1, except that each amino acid corresponding to amino acids 189 and 193 of SEQ ID NO: 1 comprises alanine or is independently substituted with any other amino acid except tyrosine, wherein the peptide further comprises comprises one or both of

(i) amino acids 1-185 of SEQ ID NO: 1, and from 0 to 2 amino acids of amino acids 1-185 of SEQ ID NO: 1 is independently substituted with any other amino acid; and

(ii) amino acids 197-218 of SEQ ID NO: 1, and from 0 to 1 amino acids of amino acids 197-218 of SEQ ID NO: 1 is independently substituted with any other amino acid; and

one or more adjuvant.

2 . The immunogenic composition of claim 1 , wherein the peptide further comprises amino acids 1-185 of SEQ ID NO: 1, and from 0 to 2 amino acids of amino acids 1-185 of SEQ ID NO: 1 is independently substituted with any other amino acid.

3 . The immunogenic composition of claim 1 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1, and from 0 to 1 amino acids of amino acids 197-218 of SEQ ID NO: 1 is independently substituted with any other amino acid.

4 . The immunogenic composition of claim 2 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1, and from 0 to 1 amino acids of amino acids 197-218 of SEQ ID NO: 1 is independently substituted with any other amino acid.

5 . The immunogenic composition of claim 1 , wherein the peptide further comprises amino acids 1-185 of SEQ ID NO: 1, and from 0 to 1 amino acids of amino acids 1-185 of SEQ ID NO: 1 is independently substituted with any other amino acid.

6 . The immunogenic composition of claim 1 , wherein the peptide further comprises amino acids 1-185 of SEQ ID NO: 1.

7 . The immunogenic composition of claim 1 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1.

8 . The immunogenic composition of claim 5 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1.

9 . The immunogenic composition of claim 6 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1.

10 . An immunogenic composition, comprising

an amino acid sequence comprising at least eight consecutive amino acids from amino acid 186 to amino acid 196 of SEQ ID NO: 1,

an adjuvant, and

a means for inhibiting binding of the amino acid sequence to Factor H.

11 . The immunogenic composition of claim 10 , wherein the adjuvant is selected from the group consisting of an aluminum salt, AS04, AS03, monophosphoryl lipid A, poly(I:C), a CpG DNA adjuvant, MF59, an emulsion adjuvant comprising squalene and water, a combination adjuvant comprising block copolymer CRL-8300, squalene, a sorbitan monooleateor, N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium salt (DOTAP), 3 β-[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-chol liposome), and a virosomal adjuvant.

12 . The immunogenic composition of claim 10 , wherein the peptide further comprises amino acids 1-185 of SEQ ID NO: 1, and from 0 to 2 amino acids of amino acids 1-185 of SEQ ID NO: 1 is independently substituted with any other amino acid.

13 . The immunogenic composition of claim 10 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1, and from 0 to 1 amino acids of amino acids 197-218 of SEQ ID NO: 1 is independently substituted with any other amino acid.

14 . The immunogenic composition of claim 12 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1, and from 0 to 1 amino acids of amino acids 197-218 of SEQ ID NO: 1 is independently substituted with any other amino acid

15 . The immunogenic composition of claim 10 , wherein the peptide further comprises amino acids 1-185 of SEQ ID NO: 1, and from 0 to 1 amino acids of amino acids 1-185 of SEQ ID NO: 1 is independently substituted with any other amino acid.

16 . The immunogenic composition of claim 10 , wherein the peptide further comprises amino acids 1-185 of SEQ ID NO: 1.

17 . The immunogenic composition of claim 10 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1.

18 . The immunogenic composition of claim 15 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1.

19 . The immunogenic composition of claim 16 , wherein the peptide further comprises amino acids 197-218 of SEQ ID NO: 1.

20 A method of vaccinating a mammalian subject against Borrelia burgdorferi, comprising

administering to the subject the immunogenic composition of claim 1 .

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2025
From: LIN, YI-PIN
To: HEALTH RESEARCH INCORPORATED
Reel/Frame 072929/0474 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2025
From: LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTER
To: HEALTH RESEARCH INCORPORATED
Reel/Frame 073150/0099 →